Zeer PhRMA / intent / phrma

PhRMA

201-500 employees·Washington, District Of Columbia, United States·phrma.org

Observed, not inferred · updated weekly

Buying intent

23 tracked signals | Top 15 topics are below.

18signals · 30 days
20topics tracked
0%attributed to a team

Attention by team

LinkedIn activity, by team

Where PhRMA's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.

Pharmacy Benefits Manager (PBM)
Clinical Trials
Patient Safety
Market Access
Oncology
Store Manager
Others
High33% of team Others to Pharmacy Benefits Manager (PBM): High, 33% of this team's signals
High22% of team Others to Clinical Trials: High, 22% of this team's signals
Medium11% of team Others to Patient Safety: Medium, 11% of this team's signals
Medium11% of team Others to Market Access: Medium, 11% of this team's signals
Medium11% of team Others to Oncology: Medium, 11% of this team's signals
Medium11% of team Others to Store Manager: Medium, 11% of this team's signals
LowMediumHigh·  banded against the busiest pairing on this page

Topics being researched

30-day window

Every tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.

Pharmacy Benefits Manager (PBM)
LinkedIn
High volume
92%
last
16d ago
Clinical Trials
LinkedIn
High volume
97%
last
20d ago
Patient Safety
LinkedIn
Medium volume
98%
last
22d ago
Market Access
LinkedIn
Medium volume
98%
last
18d ago
Oncology
LinkedIn
Medium volume
98%
last
12d ago
Store Manager
LinkedIn
Medium volume
83%
last
12d ago
Economic Growth
LinkedIn
Medium volume
96%
last
20d ago
Patient Advocacy
LinkedIn
Medium volume
96%
last
16d ago
Risk-based Monitoring
LinkedIn
Medium volume
98%
last
22d ago
Health Care Costs
LinkedIn
Medium volume
98%
last
19d ago
Career Development
LinkedIn
Medium volume
98%
last
16d ago
Workforce Management
LinkedIn
Medium volume
98%
last
19d ago
Pharmaceutical
LinkedIn
Medium volume
94%
last
16d ago
Drug Development
LinkedIn
Medium volume
98%
last
18d ago
Data Science
LinkedIn
Medium volume
96%
last
19d ago

Need intent for a specific topic or industry?

We track the full taxonomy across every account in the graph โ€” including themes not shown on this page.

Talk to us

Who's active at PhRMA

verified title on file

Titles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.

Others8 active
Executiveresearching Data Science
in
Executiveresearching Pharmacy Benefits Manager (PBM)
in
Directorresearching In-Market Accounts
in
Executiveresearching Employee Well-Being
in
VPresearching Oncology
in
VPresearching Store Manager
in

Primary products / business lines

LinkedIn company profile

We represent Americaโ€™s innovative biopharmaceutical research & biotechnology companies, advocating for policies that support the discovery of new medicines and ensure broad patient access to safe, effective treatments. PhRMA is committed to working with stakeholders in Washington, across the country and around the world to: ๐Ÿ”นExpand patient access to safe and effective medicines through a free

Top accounts researching PhRMA

names withheld on the public page

These are companies whose own people brought up PhRMA unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.

27 companies · 64 people are researching Pharmacy Benefits Manager (PBM)

PhRMA's own team shows 3 signals on this topic. No one outside PhRMA has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.

  • Clinical Trials4,086 cos · 17,225 people
  • Patient Safety2,511 cos · 10,108 people
Sign up to see which companies →

Buyer profile

company size · seniority

Company size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.

Unlock the buyer profile

Company-size breakdown and buyer seniority mix for accounts researching PhRMA.

Company size breakdown
Buyer seniority mix

Sign up to learn more

Create an account to explore buyer insights as they become available.

Sign up to learn more →

Buying committee functions

Employee job titles (LinkedIn)

Leadership โ€” 4 people

What's been said

public posts by PhRMA's team

No public post naming PhRMA has surfaced in the past year, so this is what PhRMA's own team is posting about publicly — their topics, in their words.

LinkedIn

In what was certainly a first, before a Hill meeting today, the staffer leading the meeting insisted we take advantage of a photo op. I decided to roll with it, and now my whole family wants to frame the photo. Maybe thereโ€™s a reminder here about ideas that seem crazy sometimes perhaps being great ones.

May 2026
LinkedInOpen Data

๐—จ๐—ฝ๐—ฑ๐—ฎ๐˜๐—ฒ ๐˜๐—ผ ๐—บ๐˜† ๐— ๐—ฎ๐˜† ๐Ÿญ๐Ÿญ ๐—ฝ๐—ผ๐˜€๐˜: The Andes virus sequence picture from the MV Hondius outbreak has changed โ€” and become more complicated. Open science should not require a lawyer to interpret the download button. Pathoplexus now shows ๐Ÿ๐ข๐ฏ๐ž outbreak-linked genome records. Table in Comments. One Swiss full-genome sequence has been released as ๐Ž๐ฉ๐ž๐ง through international sequence databases. Four others remain ๐‘๐—ฒ๐˜€๐˜๐—ฟ๐—ถ๐—ฐ๐˜๐—ฒ๐—ฑ-๐”๐˜€๐—ฒ ๐Ÿ๐จ๐ซ ๐—ผ๐—ป๐—ฒ ๐˜†๐—ฒ๐—ฎ๐—ฟ under Pathoplexusโ€™s outbreakโ€‘dataset policy. That split is the issue. Same outbreak. Same urgent public-health questions. Different legal status for different genomes. A journal editor or diagnostics company may be unsure whether they can incorporate all five genomes into analyses, figures, or assays without chasing bespoke permissions. For a small outbreak dataset, every genome matters. None are really โ€œbackground.โ€ Each may be central to understanding transmission, linkage, and risk. So public-health agencies, academic researchers, journals, and commercial responders are left asking: what can be used freely, what requires permission, and what is safe to publish or build on? ๐‚๐ซ๐ž๐๐ข๐ญ ๐š๐ง๐ ๐š๐ญ๐ญ๐ซ๐ข๐›๐ฎ๐ญ๐ข๐จ๐ง ๐Ÿ๐จ๐ซ ๐๐š๐ญ๐š ๐ ๐ž๐ง๐ž๐ซ๐š๐ญ๐จ๐ซ๐ฌ ๐š๐ซ๐ž ๐ž๐ฌ๐ฌ๐ž๐ง๐ญ๐ข๐š๐ฅ. But during an outbreak, sequence data should be not only visible โ€” it should be ๐—ฐ๐—น๐—ฒ๐—ฎ๐—ฟ๐—น๐˜† ๐˜‚๐˜€๐—ฎ๐—ฏ๐—น๐—ฒ.

May 2026
LinkedIn

Congratulations Emily on an insightful article and continuing to champion the need for incentives to accelerate novel antibiotic R&D.

May 2026
LinkedIn

Even as Hib disease has fallen from view, protecting children from lifeโ€‘threatening meningitis and pneumonia still depends on strong Hib vaccination as part of routine schedules, starting at birth with the HepB birth dose. This new brief highlights why sustaining high Hib coverage in childhood immunization programsโ€”alongside timely birthโ€‘dose vaccinationโ€”remains essential to prevent a resurgence of severe, vaccineโ€‘preventable infections in young children. https://lnkd.in/edEYnkWw

May 2026
LinkedInMental health coverage

Nearly one in four adults experienced a mental health condition in the past year, including more than 30% of young adults. Yet less than half of those living with these conditions receive treatment. Medications, often combined with therapy, help many, but too many people are suffering untreated. During Mental Health Awareness Month, we should be focused on expanding access, reducing stigma and ensuring patients can get the care they need when they need it. https://ow.ly/lXNS50YYg0V

May 2026

About this data. PhRMA (phrma.org). Department attribution is 0%; remaining activity is grouped under Others. Updated 2026-10-03T14:00:03.490Z.

Not yet computedPer-team narrative summaries